Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-28T16:04:08.707Z Has data issue: false hasContentIssue false
  • English
  • Français

ANXIETY AND DEPRESSION IN TUNISIAN PATIENTS WITH PARKINSON’S DISEASE

Published online by Cambridge University Press:  19 July 2023

S. Kolsi ,
E. Fakhfakh ,
N. Messedi ,
I. Chaari ,
F. Charfeddine ,
L. Aribi ,
N. Farhat ,
C. Mhiri  and
J. Aloulou
S. Kolsi*
Affiliation:
Psychiatry Department B, Hedi Chaker Hospital Sfax, Tunisia
E. Fakhfakh
Affiliation:
Neurology Department, Hbib Bourguiba Hospital, Sfax, Tunisia
N. Messedi
Affiliation:
Psychiatry Department B, Hedi Chaker Hospital Sfax, Tunisia
I. Chaari
Affiliation:
Psychiatry Department B, Hedi Chaker Hospital Sfax, Tunisia
F. Charfeddine
Affiliation:
Psychiatry Department B, Hedi Chaker Hospital Sfax, Tunisia
L. Aribi
Affiliation:
Psychiatry Department B, Hedi Chaker Hospital Sfax, Tunisia
N. Farhat
Affiliation:
Neurology Department, Hbib Bourguiba Hospital, Sfax, Tunisia
C. Mhiri
Affiliation:
Neurology Department, Hbib Bourguiba Hospital, Sfax, Tunisia
J. Aloulou
Affiliation:
Psychiatry Department B, Hedi Chaker Hospital Sfax, Tunisia
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Anxiodepressive disorders in Parkinson’s disease (PD) are quite frequent and considered as non-motor signs of the disease. Few studies have studied the link between these entities.

Objectives

The objective of this study is to determinate the prevalence of anxiety and depression in patients with PD, and factors associated with them

Methods

A descriptive and analytical cross-sectional study collected from patients followed at the neurology consultation of Habib Bourguiba’s university Hospital in Sfax, Tunisia. We used:

  • - a sociodemographic, clinical and therapeutic data sheet

  • - Hospital Anxiety and Depression Scale(HADS): to study anxiety and depression. A score ≥10 means a certain anxiety or depression

Results

We have involved 47 patients. The average age was 61.47 years with a sex ratio (M/W)=1,47. Amantadine was received by 12.77% of patients, anticholinergics by 14.9% of patients and 87.24% of patients were treated with Levodopa.

HADS: the average scale of Depression was8.62 ± 4.54 and the median scaleanxiety was 7 [1-18]. Depression and anxiety were presentin 38.29% and 27.68% of cases, respectively. Depression was significantly correlated with Amantadine intake (P=0.036) and Levodopa dose (P=0.016). Anxiety was significantly associated with anticholinergic intake(P=0.011).Both depression and anxiety were notstatistically correlated to the presence ofmotor complications of dopa therapy (P= 0.44 and 0.7 respectively)

Conclusions

The therapeutic management of patients with PD influences the occurrence of anxiety and depression, which proves the importance of early detection of these disordersto ensure better support

Disclosure of Interest

None Declared

Type
Abstract
Information
European Psychiatry , Volume 66 , Special Issue S1: Abstracts of the 31st European Congress of Psychiatry , March 2023 , pp. S961
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.